March 7, 2006

BioMS Medical has announced that its proprietary drug candidate MBP8298 delayed disease progression for five years in progressive multiple sclerosis (MS) patients with HLA-DR2 or HLA-DR4 immune response genes. Treatment and follow-up of patients from a Phase II clinical study demonstrated that patients in this DR2 and DR4 responder group, who comprise up to 75 percent of MS patients, had a median time to disease progression (worsening) of 78 months, compared to 18 months for patients who received placebo.

The findings are based on a two-year treatment and five-year follow-on study conducted and analyzed by the University of Alberta and BioMS Medical. The primary objective of the trial was to assess the clinical efficacy of 500mg of MBP8298 administrated intravenously every six months, as measured by the Expanded Disability Status Scale (EDSS). Long-term follow-up treatment and assessment of 20 progressive MS patients with the HLA-DR2 or HLA-DR4 immune response genes demonstrated a median time to progression of 78 months (6.5 years) for MBP8298 treated patients compared to 18 months (1.5 years) for patients treated with placebo in the initial study.